Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $2,286,779.95 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $46.45, for a total transaction of $2,286,779.95. Following the transaction, the insider now owns 6,926 shares of the company’s stock, valued at approximately $321,712.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Monday, September 30th, Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.24, for a total transaction of $44,297.92.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.33, for a total value of $92,364.06.

Janux Therapeutics Stock Performance

JANX stock opened at $44.50 on Wednesday. The firm has a 50 day simple moving average of $43.85 and a 200 day simple moving average of $44.68. Janux Therapeutics, Inc. has a 52 week low of $5.65 and a 52 week high of $65.60. The stock has a market cap of $2.31 billion, a P/E ratio of -36.48 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. The firm’s quarterly revenue was up 709.1% on a year-over-year basis. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research note on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. Finally, Scotiabank decreased their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.13.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of JANX. Summit Securities Group LLC acquired a new stake in shares of Janux Therapeutics during the 2nd quarter valued at about $29,000. Amalgamated Bank raised its position in Janux Therapeutics by 61.1% during the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after acquiring an additional 368 shares in the last quarter. Plato Investment Management Ltd acquired a new stake in Janux Therapeutics in the second quarter valued at approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Janux Therapeutics in the second quarter worth approximately $151,000. Finally, AQR Capital Management LLC acquired a new position in shares of Janux Therapeutics during the 2nd quarter worth $215,000. 75.39% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.